| (Values in U.S. Thousands) | Feb, 2023 | Feb, 2022 | Feb, 2021 | Feb, 2023 | Feb, 2022 |
| Sales | 0 | 0 | 78 | 0 | 0 |
| Sales Growth | unch | -100.00% | unch | unch | unch |
| Net Income | -22,836 | -22,266 | -7,035 | 0 | 0 |
| Net Income Growth | -2.56% | -216.49% | unch | unch | unch |
Small Pharma Inc (DMT.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Small Pharma Inc is a neuropharmaceutical company. It is committed towards the development of effective therapeutic treatments for mental health disorders. Small Pharma is developing N,N-dimethyltryptamine and a pipeline of novel patent-protected deuterium-enriched tryptamine compounds in combination with psychotherapy as potential rapid onset, sustained treatments for depression and other mental health disorders. It has one operating segment, research and development ("R&D") of psychedelic and nonpsychedelic medicine.
Fiscal Year End Date: 02/28